PCSK9 and non-small cell lung carcinoma: More recently a pilot study has investigated the prognostic role of PCSK9 in patients with non-small lung cancer (NSCLC), and they found that in patients with advanced, previously treated NSCLC, serum PCSK9 levels greater than 95 ng/mL at the second cycle of nivolumab therapy was an independent predictor of decreased overall survival (OS) [105].